NovoCure Limited

NASDAQ:NVCR

Medical - Instruments & Supplies

Healthcare
$10.73 -19.66%

-$3.51 today

Market cap
$1.25B
Beta
0.92
P/E (TTM)
-9.5
EPS (TTM)
-$1.52
52W Low $9.82High $18.92

Volume 1.41M

Average 1.52M

NVCR Net Income

Bottom-line profit, the starting point for calculating cash from operations.

NovoCure LimitedNASDAQ: NVCR

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $71.14M (cash outflow) rose 107.3% year over year, ahead of the +5.4% change in trailing-twelve-month net income. Sequentially, it rose 190.4% from the prior quarter. Over 3 fiscal years it compounded at +13.8% a year.

Context

  • Net income amounted to 20.8% of revenue in FY2025, down 7.1 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$122M (-10.4%) for the fiscal year ending Dec 2026, a step up from the -19.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$71.14M+190.4% QoQ
Last fiscal yearDec 2025
-$136.23M-19.2% YoY
LTMMar 2026
-$173.05M+5.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+107.3%-3.5%-110.8 pp
1 year-19.2%-10.4%+8.8 pp
3-year CAGR+13.8%-28.3%-42.1 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(136.23M) USD
Year-over-year change
+19.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NVCR compares with its peers on the latest reported figures

  • NVCR's LTM Mar 2026 net income of $173.05M is the largest of the 4 companies compared; the peer median is $21.57M.
  • Its year-over-year change of +5.4% is the 3rd highest of 4, against a peer median of +17.7%.
  • Net income amounts to 25.7% of revenue for NVCR, versus a peer median of 21.7%.
NVCR Competitors Peer median
Net Income for NVCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$173.05M +5.4%+13.8%25.7%
PLSEPulse Biosciences, Inc.LTM Jun 2026$80.06M +17.7%+7.5%6755.8%
NPCENeuroPace, Inc.LTM Mar 2026$21.57M -13.1%-23.0%21.7%
DCTHDelcath Systems, Inc.LTM Mar 2026$561K +103.9%—0.6%
Peer median (excluding NVCR) $21.57M+17.7%-7.7%21.7%

Competitors are the stored peer set for NVCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.35M)(92.53M)(207.04M)(168.63M)(136.23M)
Depreciation & Amortization10.25M10.62M10.97M(14.41M)14.65M
Deferred Income Tax3.88M0000
Stock-Based Compensation94.9M106.96M115.61M160.04M0
Change in Working Capital29.07M11.8M29.56M(4.3M)(15.13M)
Accounts Receivables5.27M2.55M29.41M(26.36M)(38.94M)
Inventory2.48M(4.34M)(8.92M)2.57M(5.67M)
Accounts Payables27.78M14.26M14.87M19.11M18.96M
Other Working Capital(6.46M)(666K)(5.8M)384K10.52M
Other Non-Cash Items3.01M(6.05M)(22.43M)932K87.67M
Operating Cash Flow82.76M30.79M(73.34M)(26.37M)(49.03M)
Capital Expenditures(24.17M)(21.36M)(27.09M)(42.86M)(26.65M)
Acquisitions (Net)120.66M118.6M000
Purchases of Investments(1.08B)(1.3B)(1B)(875.39M)(821.08M)
Sales of Investments958M1.18B1.21B778M1.29B
Other Investing Activities(120.66M)(118.6M)000
Investing Cash Flow(144.83M)(139.96M)184.15M(140.24M)437.28M
Debt Repayment(26K)(28K)(10K)84.01M(460.97M)
Common Stock Issued4.55M5.22M4.42M4.15M9.77M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities21.18M10.3M11.38M2.16M(146K)
Financing Cash Flow25.7M15.49M15.79M90.32M(451.34M)
Effect of Forex Changes(188K)(97K)131K(174K)394K
Net Change in Cash(36.56M)(93.78M)126.73M(76.47M)(62.7M)
Free Cash Flow58.59M9.43M(100.43M)(69.22M)(75.68M)

NovoCure Limited

NASDAQ:NVCR

Intrinsic Alpha fair value

Locked

Current Price

$10.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.